Zimasafe 200

Zimasafe 200
17 May

Zimasafe 200

Antibiotics & Antibacterial

- Cefixime   is a broad spectrum semi-synthetic third generation 
 cephalosporin antibiotic for oral administration. 
-The bactericidal action of Cefixime results from inhibition of cell wall 
 synthesis. Cefixime is highly beta- lactamase stable, so many bacteria that 
 resist penicillins and other cephalosporins are susceptible to Cefixime  .  
- About 40 -50 %of Cefixime is absorbed, peak serum concentrations occur 
 between 2- 6 hours after oral administration, approximately 50% of 
 absorbed dose is excreted unchanged in urine within 24 hours. 
- Cefixime has been shown to be active against most strains of the 
 following Gram-positive and Gram-negative organisms:
 Streptococcus pneumonia, Streptococcus pyogenes, Streptococcus 
 agalctiae, Haemophilus influenze, Haemophilus parainfluenzae, Moraxella 
 (Branhamella) catarrhalis, Escherichia coli, Proteus mirabilis, Proteus 
 vulgaris, Neisseria gonorrhoeae, Klebsiella pneumoniae, Klebsiella 
 oxytoca, Pasteurella multocida, Providencia species, Salmonella species, 
 Shigella species, Citrobacter diversus, Serratia marcescens.

Indecation

 Zimasafe®  is indicated for the treatment of :
- Pharyngitis, tonsillitis and sinusitis.
- Acute bronchitis. 
- Acute exacerbation of chronic bronchitis. 
- Otitis media. 
- Uncomplicated urinary tract infections.
- Uncomplicated urethral or cervical gonorrhea.  

Dosage & Administration

Adults, children over 12 years  and children over 50kg weight:
 - 400 mg daily, given as a 400mg capsule once daily or as  200mg every 12 hours. 
-For the treatment of uncomplicated urethral or cervical gonococcal 
 infections, a single oral dose of 400mg is recommended. 
Children: 
 The recommended dose is 8mg/kg/day of Zimasafe® suspension. This 
 may be administered as a single daily dose or may be given in two divided 
 doses, as 4mg/kg every 12 hours. 
Renal impairment : Zimasafe® may be administered in the presence of 
 impaired renal function as follows: 

- Each capsule of  Zimasafe® 400  contains :-
   Cefixime 400 mg (as Cefixime Trihydrate USP).
-Each capsule of  Zimasafe® 200  contains :-
   Cefixime 200 mg (as Cefixime Trihydrate USP).
-Each 5ml of  Zimasafe®  100 for oral suspention contains :-
   Cefixime 100 mg (as Cefixime Trihydrate USP).

 Zimasafe® is contraindicated in patient with known allergy to the Cefixime
  or other cephalosporins.
 Careful inquiry should be made to determine whether the patient has 
 previous hypersensitivity to Cefixime or not.

- Cefixime may increase prothrombin time, when used for patients 
 receiving anti-coagulants. 
-Carbamazepin levels elevated when administered concomitantly with  
 Zimasafe®.
- Propencid increase plasma concentration of Cefixime when administrated 
 concomitantly with Zimasafe®. 
- With food: food delay the rate of absorption of Cefixime.

- There is no adequate studies in pregnant women, so Zimasafe® should be 
 used during pregnancy only if necessary. 
-It is not known whether Cefixime is excreted in human milk or not.

 Side effects are mild and transient in nature.
-The most frequently adverse effects are: gastrointestinal disturbances as, 
 diarrhea, abdominal pain, nausea &vomiting. (Zimasafe® should be stopped 
 if diarrhea is severe).
-Other side effects, skin rashes, urticaria, transient elevation in liver enzymes.
Over dosage:-
gastric lavage may be indicated, otherwise no specific antidote exists.

 Prolonged use of antibiotic may results in over growth of non-susceptible 
 organisms, so careful observation of patient is essential. 

* Zimasafe® 400 ( Blister of 6 capsules, pack of one Blister).
* Zimasafe®  200 (Blister of 8 capsules, pack of one Blister).
* Zimasafe®  100  (Bottle of 60 ml after reconstitution).             
                              ( Bottle of 30 ml after reconstitution).

- Store in a dry place at a temperature below  25 °C.